Bainco International Investors Invests $260,000 in EXACT Sciences Co. (EXAS)

Bainco International Investors acquired a new stake in shares of EXACT Sciences Co. (NASDAQ:EXAS) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 3,000 shares of the medical research company’s stock, valued at approximately $260,000.

Other institutional investors also recently bought and sold shares of the company. First Hawaiian Bank grew its holdings in shares of EXACT Sciences by 160.0% during the 1st quarter. First Hawaiian Bank now owns 325 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 200 shares during the last quarter. Buffington Mohr McNeal bought a new position in shares of EXACT Sciences during the 1st quarter valued at $30,000. Karp Capital Management Corp bought a new position in shares of EXACT Sciences during the 4th quarter valued at $38,000. Shine Investment Advisory Services Inc. grew its holdings in shares of EXACT Sciences by 130.2% during the 1st quarter. Shine Investment Advisory Services Inc. now owns 442 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 250 shares during the last quarter. Finally, CWM LLC grew its holdings in shares of EXACT Sciences by 777.1% during the 4th quarter. CWM LLC now owns 614 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 544 shares during the last quarter. Hedge funds and other institutional investors own 87.63% of the company’s stock.

In related news, insider Mark Stenhouse sold 11,192 shares of EXACT Sciences stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $92.54, for a total transaction of $1,035,707.68. Following the completion of the transaction, the insider now directly owns 25,500 shares of the company’s stock, valued at approximately $2,359,770. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Kevin T. Conroy sold 9,169 shares of EXACT Sciences stock in a transaction dated Wednesday, February 27th. The shares were sold at an average price of $95.07, for a total transaction of $871,696.83. Following the transaction, the insider now directly owns 923,961 shares of the company’s stock, valued at $87,840,972.27. The disclosure for this sale can be found here. Over the last three months, insiders have sold 60,201 shares of company stock valued at $5,543,493. 3.20% of the stock is currently owned by corporate insiders.

Several equities analysts recently commented on the stock. Zacks Investment Research raised shares of EXACT Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, April 30th. BidaskClub raised shares of EXACT Sciences from a “buy” rating to a “strong-buy” rating in a report on Tuesday, April 16th. Finally, Canaccord Genuity lifted their target price on shares of EXACT Sciences from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, May 1st. Two analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $108.45.

Shares of EXAS opened at $95.37 on Thursday. The stock has a market cap of $12.32 billion, a PE ratio of -70.13 and a beta of 1.84. The company has a debt-to-equity ratio of 1.02, a quick ratio of 8.13 and a current ratio of 8.39. EXACT Sciences Co. has a 1-year low of $47.78 and a 1-year high of $105.28.

EXACT Sciences (NASDAQ:EXAS) last announced its earnings results on Tuesday, April 30th. The medical research company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.01). EXACT Sciences had a negative net margin of 41.58% and a negative return on equity of 28.83%. The company had revenue of $162.00 million for the quarter, compared to the consensus estimate of $153.07 million. During the same period in the previous year, the firm posted ($0.33) EPS. The company’s revenue for the quarter was up 79.4% on a year-over-year basis. Research analysts expect that EXACT Sciences Co. will post -2.13 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Bainco International Investors Invests $260,000 in EXACT Sciences Co. (EXAS)” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.com-unik.info/2019/05/16/bainco-international-investors-invests-260000-in-exact-sciences-co-exas.html.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Read More: Buy-Side Analysts

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for EXACT Sciences Co. (NASDAQ:EXAS).

Institutional Ownership by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit